Cancer testing provider Guardant Health has closed its Series B round of financing at over $30 million. The round was led by Khosla Ventures, which was joined by existing backer Sequoia Capital and new investor Pejman Mar Ventures. The additional financing will allow Guardant to accelerate the expansion of its commercial operations to support growing demand.
The new round of funding brings the company's total stash of VC capital to about $40 million, coming just a few months after a $10 million Series A financing led by Sequoia at a $40 million valuation. As part of the Series B, Khosla's Samir Kaul is joining Guardant's Board.